Literature DB >> 25165780

Phytotherapy of benign prostatic hyperplasia. A minireview.

Ester Pagano, Massimiliano Laudato, Michele Griffo, Raffaele Capasso.   

Abstract

Benign prostate hyperplasia (BPH) is a common condition affecting older men, with an incidence that is age-dependent. Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age. Typical symptoms include increased frequency of urination, nocturia, urgency, hesitancy, and weak urine stream. Conventional medicines used for the treatment of BPH include alpha blockers and 5-alpha reductase inhibitors. This articles review the mode of action, the efficacy, and the safety, including herb-drug interactions of the most common botanicals (Serenoa repens, Pygeum africanum, Urtica dioica, and Cucurbita pepo) and nutraceuticals (isoflavones, lycopene, selenium, and β-Sitosterol) in controlling the lower urinary tract symptoms associated to BPH.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25165780     DOI: 10.1002/ptr.5084

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  23 in total

Review 1.  The clinical significance and costs of herbs and food supplements used by complementary and alternative medicine for the treatment of cardiovascular diseases and hypertension.

Authors:  S G Chrysant
Journal:  J Hum Hypertens       Date:  2015-05-21       Impact factor: 3.012

2.  Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH).

Authors:  Irene Paterniti; Michela Campolo; Marika Cordaro; Rosalba Siracusa; Antonio Filippone; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Inflamm Res       Date:  2018-04-20       Impact factor: 4.575

3.  Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats.

Authors:  Shan Sasidharan; Srinivasakumar Kp; Amiya Bhaumik; Sreemoy Kanti Das; Hareebndran Nair J
Journal:  Res Rep Urol       Date:  2022-05-26

Review 4.  Current Treatment for Benign Prostatic Hyperplasia.

Authors:  Arkadiusz Miernik; Christian Gratzke
Journal:  Dtsch Arztebl Int       Date:  2020-12-04       Impact factor: 5.594

5.  Can bipolar transurethral enucleation of the prostate be a better alternative to the bipolar transurethral resection of the prostate?: A prospective comparative study.

Authors:  Mohammed Abdulwahab Al-Radhi; Lo Ka Lun; Mohammed Safi; Abdullah Al-Danakh; Khaled M Al-Kohlany; Amr Al-Najar; Hesham Al-Sharani; Mahmoud Al-Azab; XianCheng Li; Chao Wang
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 6.  Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update.

Authors:  Fouad Aoun; Quentin Marcelis; Thierry Roumeguère
Journal:  Res Rep Urol       Date:  2015-08-19

7.  Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.

Authors:  Jing Li; Yanxin Tian; Shimeng Guo; Haifeng Gu; Qianting Yuan; Xin Xie
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

8.  Methylated CpG dinucleotides in the 5-α reductase 2 gene may explain finasteride resistance in benign prostatic enlargement patients.

Authors:  Zhe-Min Lin; Dong-Dong Fan; Song Jin; Zhan-Liang Liu; Yi-Nong Niu
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

Review 9.  Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review.

Authors:  Tommaso Castelli; Giorgio Ivan Russo; Giulio Reale; Salvatore Privitera; Mario Chisari; Eugenia Fragalà; Vincenzo Favilla; Sebastiano Cimino; Giuseppe Morgia
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

10.  The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.

Authors:  Woong Jin Bae; Hyo Jung Park; Hye Cheong Koo; Do Ram Kim; U-Syn Ha; Kang Sup Kim; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Sung Yeoun Hwang; Sae Woong Kim
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.